Program
Bortezomib
Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.
Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 285 open or running | phase 4since Oct 15, 2014 | Sep 13, 2005 | Feb 14, 2029phase 3 · NCT04923893 |
| Takeda | 250 open or running | phase 4since Nov 18, 2005 | Oct 28, 2002 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Apr 24, 2006 | Apr 19, 2006 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Aug 19, 2016 | Dec 2027phase 3 · NCT06158841 |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Oct 28, 2002.
- Aug 9, 2005Phase 1 study in NeoplasmsNCT00129207 · United States
- Nov 18, 2005Phase 4 study in Multiple MyelomaNCT00257114 · United States
- Jan 27, 2006Phase 2 study in NSCLCNCT00283634 · United States
- Mar 1, 2006Phase 2 study in AmyloidosisNCT00298766 · 70 enrolled · United States
- Apr 7, 2006Phase 3 study in Lymphoma, Non-HodgkinNCT00312845 · 676 enrolled · United States, Argentina, Australia and more
- Jun 22, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00343720 · Belgium
- Sep 14, 2007Phase 2 study in Multiple MyelomaNCT00531453 · 98 enrolled · Austria
- Jan 23, 2008Phase 1 study in Multiple MyelomaNCT00608907 · 61 enrolled · Israel, Italy, Poland and more
- Jan 28, 2008Phase 2 study in Ovarian NeoplasmsNCT00610792 · 91 enrolled · Italy, Switzerland
- Jul 11, 2008Phase 2 study in Lymphoma, FollicularNCT00715208 · 55 enrolled · United States, Puerto Rico
- Jul 23, 2008Phase 3 study in Lymphoma, Mantle-CellNCT00722137 · 487 enrolled · United States, Austria, Belgium and more
- Feb 24, 2009Phase 2 study in Lymphoma, FollicularNCT00850499 · 12 enrolled · France, Germany, Greece and more
- Jul 1, 2009Phase 2 study in Acromesomelic dysplasia, Maroteaux typeNCT00931918 · 206 enrolled · United States
- Dec 29, 2009Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT01040871 · 164 enrolled · Belgium
TargetBeta
“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| carfilzomibrule | Amgen | phase 4 | 38 |
Studies
All 25 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01040871Lymphoma, Large B-Cell, Diffuse · Belgium | 2 | Completed | Jun 2012 | 164 |
| NCT00931918Acromesomelic dysplasia, Maroteaux type · United States | 2 | Completed | Aug 2015 | 206 |
| NCT00850499Lymphoma, Follicular · France, Germany, Greece and more | 2 | Terminated | Sep 2011 | 12 |
| NCT00722137Lymphoma, Mantle-Cell · United States, Austria, Belgium and more | 3 | Completed | Jan 1, 2014 | 487 |
| NCT00715208Lymphoma, Follicular · United States, Puerto Rico | 2 | Completed | Feb 2011 | 55 |
| NCT00610792Ovarian Neoplasms · Italy, Switzerland | 2 | Withdrawn | Sep 2009 | 91 |
| NCT00608907Multiple Myeloma · Israel, Italy, Poland and more | 1 | Completed | Mar 2010 | 61 |
| NCT00531453Multiple Myeloma · Austria | 2 | Completed | Apr 2009 | 98 |
| NCT00343720Carcinoma, Non-Small-Cell Lung · Belgium | 2 | Completed | Oct 2007 | |
| NCT00312845Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more | 3 | Completed | Jun 2010 | 676 |
| NCT00298766Amyloidosis · United States | 2 | Completed | Jul 2009 | 70 |
| NCT00283634NSCLC · United States | 2 | Terminated | Jul 2007 | |
| NCT00257114Multiple Myeloma · United States | 4 | Completed | Mar 2007 | |
| NCT00129207Neoplasms · United States | 1 | Completed | Sep 2006 | |
| NCT00117351Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Jun 2007 | |
| NCT00111319Multiple Myeloma · United States | 3 | Completed | Jul 2007 | |
| NCT00085696Lymphoma, B-Cell · United States | 2 | Completed | Apr 2006 | 66 |
| NCT00080405Multiple Myeloma | 1 | Completed | Jun 2005 | 40 |
| NCT00064636Advanced Non-Small Cell Lung Cancer | 1 | Terminated | 46 | |
| NCT00064610Prostatic Neoplasms · United States | 2 | Completed | Dec 2004 | 102 |
| NCT00063726Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | May 2005 | 600 |
| NCT00063713Lymphoma, Mantle-Cell · United States | 2 | Completed | Dec 2005 | 152 |
| NCT00051987Colorectal Neoplasms · United States | 2 | Completed | Mar 2004 | 175 |
| NCT00051974Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Sep 2004 | 155 |
| NCT00048230Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Jul 2004 | 620 |
How it is read
Names in the registry
- “Bortezomib”, 42 entries
- “bortezomib”, 18 entries
- “VELCADE”, 6 entries
- “VELCADE TM (bortezomib) for Injection”, 2 entries
- “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 61 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Lymphoma, Mantle-Cell, 3 studies
- Lymphoma, Follicular, 3 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.